Here’s what’s in store for you in today’s issue:
🍄 Psychedelic therapy enters the Metaverse?!
🍄 Kids try ketamine
🍄 How psychedelics help you manage stress
🍄 Microdosing for a better sleep
🍄 And more.
In the episode of the Daily Mushroom Podcast, we have Tony Shields, CEO of FreshCap. Tony’s knowledge on mushrooms is deep and expansive and stems from a childhood fascination with these magnificent fungi. If you want to learn more about the benefits of functional mushrooms, this podcast is for you.
Psychedelic drug users had less psychological distress and more social support during pandemic lockdowns, according to a recent Tilburg University survey.
Users were more likely to spend time outdoors, maintain healthy diets, meditate, play music, and do yoga. Non-users spent more time watching TV and following COVID news.
A new study found that people who used psychedelics within the past six months were 55% less likely to use opioids daily.
MindMed (MNMD) launched a study to investigate the effects of microdosing LSD in the morning versus the evening.
Researchers will use digital devices and software to track:
Clearmind Medicine’s (CMND) proprietary compound could treat alcohol addiction, but that’s not all. It is now being evaluated to treat other addictive behaviours such as compulsive consumption of food, television, technology, shopping, gambling, and even sex.
A study discovered that psilocybin can reduce the odds of alcohol relapse!
How does it work? Alcohol reduces a protein in the brain called mGluR2. In a rat model, researchers found that the more protein lost, the more alcohol the rats craved, creating an addictive cycle.
Psilocybin was able to restore protein levels, thus decreasing relapses.
Tennessee-based ketamine company Revitalist (CALM) announced that it’s developing a mental health clinic in the Metaverse 🤯
Patients will be able to attend VR therapy sessions, pay with cryptocurrency, and earn NFTs as part of a rewards program.
Most parents think they should!
A survey shows that parents, especially those who have experienced mental illness, are very open to ketamine therapy for children. The average acceptance score was 7/10 and over 60% said they would allow their child to try ketamine therapy to treat depression.
These companies announced their quarterly highlights:
A psychiatrist is suing the Australian state of Victoria for denying a patient access to MDMA-assisted therapy. The case has been adjourned until early next year, as the government may decide to reschedule MDMA from a Schedule 9 to a Schedule 8 substance.
Researchers in Australia are training oyster mushrooms to digest cigarette butts, including their microplastics. The goal is to turn some of the 4.5 trillion cigarette butts that are littered annually into a reusable material!
Try FreshCap’s Mushroom Coffee to have the most productive day ever!
Made with organic Lion’s Mane mushrooms to support cognition, immune-boosting Chaga, and stress-relieving Ashwagandha, it’s everything you love about coffee – made even better.
Use promo code DAILY for 10% off your order at FreshCaps.com!
You’re welcome in advance 😉
Nov 15 – Lobe Sciences Announces Common Stock to Trade Under the Symbol “LOBEF” in US Markets Read more…
Nov 16 – Michael J. Fox Foundation Donates $2M to Fund Ketamine Trial to Treat Depression in Patients with Parkinson’s Disease Read more…
Nov 16 – Ketamine One (MEDI) Subsidiary IRP Health Opens Two New Veteran-Focused Clinics in Comox Valley and Ottawa Read more…
Nov 17 – Pasithea Therapeutics (KTTA) Expands At-Home Ketamine Therapy to New York City, Los Angeles, San Diego, and San Francisco Read more…
Nov 19 – Numinus to Begin Trading on the OTC Under Symbol “NUMIF” Read more…
Nov 19 – PsyBio Therapeutics Furthers Intellectual Property Portfolio with Six New Manufacturing Patent Applications Read more…
